EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Documenti analoghi

• Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen
  di: Menke, Marcel N, et al.
  Pubblicazione: (2014)
• Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab
  di: Ebneter, Andreas, et al.
  Pubblicazione: (2016)
• Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
  di: Ebneter, Andreas, et al.
  Pubblicazione: (2020)
• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial
  di: Ohji, Masahito, et al.
  Pubblicazione: (2020)
• Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
  di: Menke, Marcel N., et al.
  Pubblicazione: (2016)